Aeglea BioTherapeutics Investor Presentation Deck

Potential best-in-class lead programs DESIGN ATTRIBUTES SPY001 (α437) IDENTICAL EPITOPE TARGETING AS VEDOLIZUMAB COMPARABLE POTENCY AND SELECTIVITY AS VEDOLIZUMAB SC EXTENDED HALF-LIFE mAb TO ENABLE Q8-12W REGIMEN INTERIM HV PK DATA EXPECTED YE 2024 SPYRE SPY002 (TL1A) DUAL MONOMER AND TRIMER BINDER PICOMOLAR POTENCY AGAINST MONOMERS AND TRIMERS SC EXTENDED HALF-LIFE mAb TO ENABLE Q8-12W REGIMEN INTERIM HV PK DATA EXPECTED 1H 2025 COMBINATIONS ✓ONLY KNOWN PORTFOLIO WITH a437, TL1A, AND IL-23 ✓ POTENTIAL TO ADDRESS ORTHOGONAL BIOLOGY TARGETING UNIFIED SC Q8-12W DOSING INITIATION EXPECTED AFTER PH1 DATA 4

View entire presentation